Sponsored Link:

Page Analysis

Sponsored Link:


Home - Fresenius Kabi USA, LLC
No description found
610 ratings.1016 user reviews.

Web page information

  1. Title
    Home - Fresenius Kabi USA, LLC
  2. Keywords hit in search results
  3. Captured Content
    APP: A Division of Fresenius Kabi USA. Fresenius Kabi USA, LLC Executive Management. Fresenius Kabi USA, LLC Corporate Governance. Fresenius Kabi USA, LLC Corporate Responsibility. Environmental, Health and Safety. Heparin Supply Chain Integrity. Stabilizing the Heparin Marketplace. Working Together for Patient Safety. Prescription Writing Do's and Don'ts.Common Mistakes. USP Standards for Unfractionated Heparin. FAQs - Fresenius Kabi USA, LLC UFH Products. FAQs - Clinical Considerations. Heparin Supply Chain Integrity. Stabilizing the Heparin Marketplace. ru - free extensions for joomla. New Products Product Updates Product Videos Order Information Product Availability Information Exhibitions and Events. Fresenius Kabi is focused on the care of critically and chronically ill patients inside and outside the hospital. Its portfolio of products comprises a wide range of IV drugs, infusion therapies, clinical nutrition products as well as the related medical devices and blood transfusion technologies. With a corporate philosophy of Caring for Life, the company's goal is to improve the patient's quality of life. Fresenius Kabi AG is a 100 percent subsidiary of the health care group Fresenius SE and Co. For more information, visit www.fresenius-kabi.com. In the United States, APP, a division of Fresenius Kabi USA, LLC markets a broad portfolio of specialty pharmaceutical products with a focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets for use in hospitals, long-term care facilities, alternate care sites and clinics. Product News and Information. Fresenius Kabi Announces Availability of Acetylcysteine Solution, USP. Fresenius Kabi Announces Launch of Oxaliplatin Injection, USP Latest APP Oncology Product Now Available. APP Pharmaceuticals Acquires Three Products From Nexus. Benztropine Mesylate, Levetiracetam and Tranexamic Acid Injectables are Newest Additions to Critical Care Portfolio. APP Pharmaceuticals Announces Approval of Preservative-Free Methotrexate Injection, USP. APP Pharmaceuticals Announces Launch of Imipenem and Clilastatin for Injection, USP and Meropenen for Injection, USP. Propofol Authorized Distributors (Updated Nov. Fresenius Propoven 1% (propofol 1%). Heparin Sodium Injection, USP. Topotecan Hydrochloride for Injection. New to Critical Care Portfolio. Benztropine Mesylate Injection, USP. Tranexamic Acid Injection (vial). All Rights Reserved, Fresenius Kabi USA, LLC December 2012.
  4. Captured Keywords
    order information, about us, fact sheets, history, our mission, locations worldwide, john ducker, frank harmon, steven j, adams, jack silhavy, scott w, meacham, brent eck, james w, callanan, audit committee, supplier relations, employee safety, strategic involvement, tactical involvement, our products, alphabetical, brandtogeneric, latex information, new products, preservative free, tallman labeling, product updates, therapeutic class, product sites, heparin, diprivan, naropin, patient safety, labeling, bar coding, ihi recommendations, patients, press releases, contact, rss feeds, careers, job openings, benefits, jtemplate, search products, select, kgaa, analgesics/anesthetics, blood modifiers, oncolytics, levetiracetam injection, customer letter, sales aid, site map, imprint
No Coupons found for this website.

500 characters left

Your Review: (5 out of 5)
refresh captcha

Server Information
IP Address:
Server:Apache/2.2.3 (CentOS)
Powered By:PHP/5.2.10
Site Disclaimer:

All trademarks are the property of their respective owners. The facts, figures, reviews, records, stats, and other data presented on this page is for suggestion and information purposes only. PageGlimpse.com is not responsible for any incorrect or incomplete information. PageGlimpse.com does not take responsibility for any user-reviews of websites inside its resource and reserves the right to keep or remove those. It is highly recommended that you review all the data for accuracy.